Mometasone furoate nasal spray for the treatment of elderly patients with perennial allergic rhinitis.

摘要

The predicted doubling of the population older than 65 years by 2030 will likely lead to increased numbers of elderly patients with allergic rhinitis (AR). Intranasal corticosteroids have proven safety and efficacy in adults with AR. In-class differences in frequency of administration and bioavailability are particularly relevant to elderly patients. A literature review found that clinical trials in adults with perennial AR (PAR) typically included those 65 years and older but did not report data specific to this population. One study was identified assessing fluticasone propionate in elderly patients with rhinitis, but it included those with allergic and nonallergic disease. We present the first data from a 12-week study of 334 patients 65 years and older with PAR who received either once-daily mometasone furoate nasal spray, 200 mug, or placebo.